Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcus Biosciences, Inc. Common Stock
(NY:
RCUS
)
9.340
-0.200 (-2.10%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arcus Biosciences, Inc. Common Stock
< Previous
1
2
3
4
5
6
Next >
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
February 26, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
February 25, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
February 24, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
February 18, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
February 18, 2025
From
Arcus Biosciences
Via
Business Wire
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
February 15, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
February 11, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium
February 10, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
January 24, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
January 21, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
December 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
December 19, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
December 10, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
December 03, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
November 19, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
November 12, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
November 06, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
November 05, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
October 30, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 24, 2024
From
Arcus Biosciences
Via
Business Wire
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
October 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
October 22, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 09, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
October 09, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
October 02, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 10, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
August 27, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
August 26, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
August 21, 2024
From
Arcus Biosciences
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
